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HIV affects almost 37.9 million persons globally, and an estimated 1.7 million new HIV infections
occur in 2018 (1). While HIV/AIDS is taking a devastating toll on populations’ health, lives
and families, the disease is imposing a serious economic burden on governments (2–4) being
classified as the greatest single financial burden on healthcare systems globally (5). This burden
is predominantly due to the high payments of antiretroviral therapy (ART), hospitalizations, and
associated opportunistic infections treatment (6, 7). In Portugal, HIV continues to be amajor public
health concern and HIV prevalence is among the highest in Europe (8, 9) with 41,000 individuals
who are living with HIV, representing 0.5% of the total population (10) (see Table 1 for an
informative overview of HIV/AIDS in Portugal). The country also still records annual rates of new
HIV/AIDS diagnosis, which have been classified among the highest in the European Union (EU)
(8). Admissions among HIV/AIDS patients still pose considerable challenges to the Portuguese
national health system (5, 11). In Portugal, hospitalizations related to HIV/AIDS are some of the
most expensive with an average daily cost of e825 and an average length of stay of 23 days, placing
HIV/AIDS as the second greatest Major Diagnostic Category (MDC) (5, 12). In addition, and
after the financial crisis that hit Portugal in 2011, the country went through strict fiscal austerity
that resulted in budget cuts, reduction of spending on sensitive health sectors, and restructuring
numerous public entities including the National AIDS Program (NAP) (12–14). It is important to
know that the average cost of HIV treatment in Portugal is about 14,000e/patient per year (6). The
main cost driver is the antiretroviral medications (e 9,598), followed by hospitalizations (e 1,323).
Treatment costs grow with the severity of disease from e 11,901, with a CD4 count more than 500,
to e 23,351, with a CD4 count <50 (6). In other words, while cost related to antiretroviral remains
constant over the course of the disease, the cost progression remains mainly linked to the associated
hospitalizations and admissions related to HIV. Moreover, the shift of HIV infection from a fatal
disease into a chronic illness carries substantial challenges to the health system. The introduction
of antiretroviral therapy (ART) has dramatically increased the life expectancy of HIV patients (15–
17). This modification in the natural evolution of HIV infection has led to a substantial increase in
the financial burden and cost due to the net increase in the number of people living with HIV and
the associated life-long treatment and comorbidities (16, 18).
Shaaban and Martins Quality Among HIV/AIDS Hospitalizations in Portugal
TABLE 1 | HIV/AIDS estimates in Portugal.
Adults aged 15 and over living with HIV 41,000 (CI: 36,000–46,000)
Adult aged 15–49 HIV prevalence rate 0.5 (CI: 0.4–0.5)
HIV incidence per 1,000 population (adults 15–49) 0.10
People living with HIV who are on ART 37,000
Percent of people living with HIV who are on ART 90 (CI: 78–95)
Average cost of HIV treatment per year 14,277 e/patient*
Sources: UNAIDS, *Perelman et al. (6).
CI, Confidence Interval.
In this context, one possible solution to overcome this
associated economic burden is to increase value in healthcare
by integrating quality measures of hospitals’ performance while
reducing the costs of healthcare. Previous reviews supported
the evidence that there is great potential for decreasing costs
by targeting deficiencies in quality, and accordingly we can
maximize the benefits given the available resources (19–24). Two
important quality measures had obtained growing attention as
a benchmark indicator for measuring hospital’s performance,
thirty-day readmission rate, and length of stay (LOS) (22, 25–28).
However, despite being optimal methods for assessing hospital’s
performance, there remains a scarcity of research pertaining
to the factors that can influence these quality indicators,
especially when it comes to assessing hospitalizations among
HIV/AIDS patients in Portugal. Thirty-day hospital readmission
is defined as an episode in which a patient is readmitted
within 30 days from the last discharge. Early readmission
rates have increasingly been used as an outcome measure
in health services research and as a quality benchmark for
health systems (29–31). However, although often preventable,
early readmissions have been recognized as frequent and costly
events (32–34). For example, in the United States, one in five
Medicare beneficiaries has 30-days readmission, with a cost
of around $26 billion per year (34, 35). Accordingly, hospital
readmission rates were incorporated in the reimbursement
decisions for several programs, in which the health systems
penalize hospitals with higher than expected readmission
rates (33, 36).
The second quality indicator is length of stay which is
defined as the number of days a patient is hospitalized in
relation to the admission diagnosis and it had been widely used
to evaluate the effect of implementing patient group related
reimbursement systems in the form of Diagnosis Related Groups
systems (DRG) is length of stay (37, 38). This quality indicator
has been recommended as an important outcome measure for
quality improvement activities (28). Using length of stay as a
hospital performance measure will allow us to impact cost and
quality through payment incentives for hospitals or health care
providers. For example, if a hospital reduces length of stay and
accordingly the other associated resources and costs, the hospitals
will be more efficient through maintaining a higher marginal
return on each per admission payment (22).
The Portuguese national database of admissions among
HIV patients can be obtained for research purposes from
the Administration of the Health System (ACSS) (39). These
data are anonymous, refers to the Diagnosis Related Groups
(DRGs), and each record corresponds to a discharge episode
and contains information collected while the patients were
admitted to the hospital. These data include information about
length of stay as well as information collected during the
hospitalization that include socio-demographic characteristics
(age, sex, region of residence), dates of hospitalization and
discharge, Index hospitalization (admission type (urgent or
scheduled), type of intervention (surgical or medical), type of
diagnosis (primary and secondary diagnoses), type of procedures
during the hospitalization), prior health care utilization (mode of
transfer, destination after discharge), outcome at discharge (alive
or deceased), coverage by the national health system (Yes/No).
To determine 30-day readmission for each hospitalization, a
unique fictional code included in the data can be used since it
allows determining how many episodes correspond to the same
user, in the same institution. This fictional code does not identify
the user nor allow its identification afterward. Accordingly,
readmission episodes and the time span between the readmission
and the last discharge can be calculated for each hospitalization.
accordingly, The variable of interest can be created as follows: Y
= 0 if hospitalizations without subsequent 30-day readmission,
Y = 1 if hospitalizations with subsequent 30-day readmission(s).
Univariate and multivariate logistic models can be estimated
afterward to identify the determinants of hospitalizations with
subsequent 30-day readmission.
Regarding length of stay, each hospitalization is associated
with a record that refers to the number of days each person
remains at hospital as a count data. However, giving the statistical
nature of length of stay as count data, caution should be
taken when handling such data with count distribution [for an
informative overview of count distribution see (40)]. Using the
most common techniques, namely the ordinary least squares
(OLS) or logistic regression to handle a dependent variable with
positive skewness as occurs in LOS, will violate the fundamental
assumptions behind each technique (41, 42). Accordingly, this
may result in biased and inefficient estimates and produce
results that do not accurately reflect the observed data (41,
42). Fortunately, count statistical techniques (Poisson, negative
binomial, Zero Inflated Poisson, and Zero Inflated Negative
Binomial models) have been developed to handle count data on
a dependent variable and can replace these suboptimal statistical
strategies (43, 44). Using these count regression techniques will
allow us to accurately determine the factors that can push
length of stay further. Moreover, the conceptual and statistical
advantages of each count model should be illustrated precisely
since the accuracy and nature of results tend to vary depending
on the specific model utilized.
This opinion contributes to the attempts on reducing the
economic burden of HIV in Portugal, which is in line with
Portugal’s policy of cost reduction as a target to stabilize the
economic situation. Our opinion point to other concerns that
need to be considered: integration of quality measures as a
method of evaluating hospitals’ performance is crucial in the
light of limited resources and should be considered as a national
priority. A considerable work should be devoted to controlling
and investigating the factors which tend to push 30-day
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admission rate and length of stay expenses further. The statistical
nature of quality measures requires a deep understanding of the
appropriate statistical models that should be used to avoid biased
estimates. Finally, there is a potential in policy decision-making
concerning the optimal use of limited resources and as a first
step, we should deeply investigate the determinants of 30-days
readmission and length of stay among HIV patients in Portugal.
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